Piper Sandler Downgrades Abiomed to Neutral, Raises Price Target to $380
Piper Sandler analyst Matt O'Brien downgrades Abiomed (NASDAQ:ABMD) from Overweight to Neutral and raises the price target from $350 to $380.
Abiomed Completes All Impella Post-Approval Studies For High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock And Right Heart Failure
Abiomed (NASDAQ:ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps. The
Mizuho Initiates Coverage On Abiomed with Buy Rating, Announces Price Target of $300
Mizuho analyst Anthony Petrone initiates coverage on Abiomed (NASDAQ:ABMD) with a Buy rating and announces Price Target of $300.
Abiomed Highlights Multi-Society Study Of Impella-supported Patients
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Morgan Stanley Maintains Underweight on Abiomed, Lowers Price Target to $235
Morgan Stanley analyst David Lewis maintains Abiomed (NASDAQ:ABMD) with a Underweight and lowers the price target from $275 to $235.